CR looked at the nutritional content of Lunchly kits and tested them for lead, other heavy metals, and plasticizers. Are they ...

World markets have hunkered down for three days of economic health checks, corporate readouts and policy decisions that may ...

Maziar Mike Doustdar takes over at Novo Nordisk as the company reports weaker earnings than expected on generic challenges to ...

European stocks closed higher on Tuesday, buoyed by financials and defence stocks, though Danish stocks logged their biggest ...

Simple lifestyle changes like diet, exercise and social support may prevent dementia and improve cognitive aging by up to two ...

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...

Add in the ongoing headlines surrounding Paramount and Skydance’s merger, which also seems to have the president in its orbit ...

The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?

Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

The Global Metabolism Drugs Market, valued at approximately USD 16.10 billion in 2022, is projected to grow at a robust CAGR of more than 6.50% during the forecast period from 2023 to 2030. Metabolism ...

According to Research by SNS Insider, The U.S. GLP-1 Receptor Agonist Market to Reach USD 113.13 Billion by 2032, Driven by Rising Prevalence of Type 2 Diabetes and Demand for Obesity-Related ...